{"id":10167,"date":"2026-05-24T13:40:24","date_gmt":"2026-05-24T11:40:24","guid":{"rendered":"https:\/\/nexxusbio.com\/?p=10167"},"modified":"2026-10-06T11:15:24","modified_gmt":"2026-10-06T09:15:24","slug":"ipamorelin-cjc-1295-is-not-available","status":"publish","type":"post","link":"https:\/\/nexxusbio.com\/en\/ipamorelin-cjc-1295-no-dac\/","title":{"rendered":"Ipamorelin and CJC-1295 No DAC: receptor signaling in research"},"content":{"rendered":"

Ipamorelin a CJC-1295 No DAC<\/strong> sa v research-grade katal\u00f3goch objavuj\u00fa v s\u00favislosti s laborat\u00f3rnym v\u00fdskumom regul\u00e1cie somatotropnej osi, receptorovej signaliz\u00e1cie a mechanizmov spojen\u00fdch s rastov\u00fdm horm\u00f3nom (GH). Ide v\u0161ak o dve odli\u0161n\u00e9 peptidov\u00e9 molekuly, ktor\u00e9 sa sk\u00famaj\u00fa prostredn\u00edctvom rozdielnych receptorov\u00fdch dr\u00e1h.<\/p>\n

Pri interpret\u00e1cii dostupnej literat\u00fary je mimoriadne d\u00f4le\u017eit\u00e9 rozli\u0161ova\u0165 medzi \u00fadajmi pre Ipamorelin<\/strong>, klasick\u00fdm GRF(1-29)<\/strong>, dlho p\u00f4sobiacim CJC-1295 s DAC<\/strong> a materi\u00e1lom ozna\u010dovan\u00fdm v research katal\u00f3goch ako CJC-1295 No DAC \/ Mod GRF 1-29<\/strong>. Tieto ozna\u010denia nemo\u017eno automaticky pova\u017eova\u0165 za analyticky alebo farmakologicky zamenite\u013en\u00e9.<\/p>\n

In short:<\/strong> Ipamorelin patr\u00ed medzi syntetick\u00e9 growth hormone secretagogues sk\u00faman\u00e9 v s\u00favislosti s GHS receptorovou dr\u00e1hou. Ozna\u010denie CJC-1295 No DAC sa v research katal\u00f3goch pou\u017e\u00edva pre kr\u00e1tko p\u00f4sobiace anal\u00f3gy GRF(1-29), zatia\u013e \u010do hlavn\u00e9 publikovan\u00e9 klinick\u00e9 pr\u00e1ce s CJC-1295 sk\u00famali dlhodobo p\u00f4sobiacu formu s album\u00ednovou v\u00e4zbou. Pre samotn\u00fa kombin\u00e1ciu Ipamorelin + CJC-1295 No DAC preto nemo\u017eno automaticky prebera\u0165 v\u00fdsledky zo \u0161t\u00fadi\u00ed jednotliv\u00fdch alebo odli\u0161n\u00fdch molekulov\u00fdch foriem.<\/div>\n

\u010co je Ipamorelin?<\/h2>\n

Ipamorelin<\/strong> je syntetick\u00fd pentapeptid, ktor\u00fd bol vyvinut\u00fd ako growth hormone secretagogue. P\u00f4vodn\u00e1 farmakologick\u00e1 pr\u00e1ca Raun et al. z roku 1998 hodnotila jeho vlastnosti v kult\u00farach hypofyz\u00e1rnych buniek a v zvierac\u00edch modeloch.<\/p>\n

V tejto pr\u00e1ci Ipamorelin stimuloval uvo\u013e\u0148ovanie GH prostredn\u00edctvom receptorovej dr\u00e1hy typickej pre skupinu GHRP\/GHS. Autori z\u00e1rove\u0148 pozorovali odli\u0161n\u00fd hormon\u00e1lny profil v porovnan\u00ed s niektor\u00fdmi star\u0161\u00edmi growth hormone secretagogues.<\/p>\n

D\u00f4le\u017eit\u00e9 v\u0161ak je, \u017ee ve\u013ek\u00e1 \u010das\u0165 t\u00fdchto mechanistick\u00fdch \u00fadajov poch\u00e1dza z in vitro a zvierac\u00edch modelov<\/strong>. Nemo\u017eno ich preto automaticky interpretova\u0165 ako potvrden\u00fd \u00fa\u010dinok u \u010dloveka alebo ako vlastnos\u0165 konkr\u00e9tneho komer\u010dn\u00e9ho research-grade materi\u00e1lu.<\/p>\n

Primary source: Raun et al. \u2013 Ipamorelin, the first selective growth hormone secretagogue<\/strong><\/a>.<\/p>\n

Growth hormone secretagogue receptorov\u00e1 dr\u00e1ha<\/h2>\n

Receptorov\u00e1 signaliz\u00e1cia growth hormone secretagogues bola predmetom intenz\u00edvneho v\u00fdskumu u\u017e v 90. rokoch. V roku 1996 bol identifikovan\u00fd G-prote\u00ednov\u00fd receptor pr\u00edtomn\u00fd okrem in\u00e9ho v hypof\u00fdze a hypotalame, ktor\u00fd reagoval na syntetick\u00e9 GH secretagogues.<\/p>\n

Tento objav pomohol objasni\u0165, pre\u010do m\u00f4\u017eu GHRP\/GHS zl\u00fa\u010deniny ovplyv\u0148ova\u0165 signaliz\u00e1ciu spojen\u00fa so sekr\u00e9ciou GH odli\u0161n\u00fdm mechanizmom ne\u017e rastov\u00fd horm\u00f3n uvo\u013e\u0148uj\u00faci horm\u00f3n (GHRH).<\/p>\n

Primary source: Howard et al. \u2013 A receptor in pituitary and hypothalamus that functions in growth hormone release<\/strong><\/a>.<\/p>\n

\u010co je CJC-1295 No DAC \/ Mod GRF 1-29?<\/h2>\n

V research-grade katal\u00f3goch sa n\u00e1zov CJC-1295 No DAC<\/strong> \u010dasto pou\u017e\u00edva spolu s ozna\u010den\u00edm Modified GRF(1-29)<\/strong> or Mod GRF 1-29<\/strong>. Pri pr\u00e1ci s vedeckou literat\u00farou je v\u0161ak potrebn\u00e9 d\u00e1va\u0165 pozor na nomenklat\u00faru.<\/p>\n

GRF(1-29) predstavuje biologicky akt\u00edvny N-termin\u00e1lny fragment growth hormone-releasing factor. Experiment\u00e1lne pr\u00e1ce uk\u00e1zali, \u017ee GRF(1-29) m\u00f4\u017ee aktivova\u0165 GHRH receptorov\u00fa signaliz\u00e1ciu a \u017ee nat\u00edvne GRF fragmenty podliehaj\u00fa proteolytick\u00e9mu \u0161tiepeniu, napr\u00edklad prostredn\u00edctvom dipeptidyl peptid\u00e1zy IV (DPP-IV).<\/p>\n

Prim\u00e1rny zdroj k degrad\u00e1cii GRF: Bongers et al. \u2013 Kinetics of dipeptidyl peptidase IV proteolysis of growth hormone-releasing factor and analogs<\/strong><\/a>.<\/p>\n

\n

D\u00f4le\u017eit\u00e1 nomenklat\u00farna pozn\u00e1mka:<\/strong><\/p>\n

Publikovan\u00e9 \u0161t\u00fadie ozna\u010den\u00e9 jednoducho ako \u201eCJC-1295\u201c sa nesm\u00fa automaticky interpretova\u0165 ako \u0161t\u00fadie CJC-1295 No DAC. P\u00f4vodn\u00fd CJC-1295 bol vyvinut\u00fd ako modifikovan\u00fd GRF anal\u00f3g schopn\u00fd v\u00e4zby na s\u00e9rov\u00fd album\u00edn, \u010do v\u00fdrazne predl\u017eovalo jeho expoz\u00edciu. Pri citovan\u00ed \u00fadajov je preto v\u017edy potrebn\u00e9 skontrolova\u0165, ktor\u00e1 molekulov\u00e1 forma bola v konkr\u00e9tnej pr\u00e1ci skuto\u010dne sk\u00faman\u00e1.<\/p>\n<\/div>\n

CJC-1295 s DAC verzus ozna\u010denie No DAC<\/h2>\n

P\u00f4vodn\u00e1 publikovan\u00e1 molekula CJC-1295<\/strong> obsahovala chemick\u00fa modifik\u00e1ciu navrhnut\u00fa na v\u00e4zbu na s\u00e9rov\u00fd album\u00edn. Jett\u00e9 et al. v roku 2005 op\u00edsali t\u00fato molekulov\u00fa kon\u0161trukciu ako dlho p\u00f4sobiaci anal\u00f3g hGRF(1-29).<\/p>\n

V experiment\u00e1lnom modeli sa po podan\u00ed vytvorila album\u00ednom viazan\u00e1 forma, ktor\u00e1 zost\u00e1vala v cirkul\u00e1cii v\u00fdrazne dlh\u0161ie ne\u017e samotn\u00fd kr\u00e1tky GRF fragment.<\/p>\n

Primary source: Jett\u00e9 et al. \u2013 Identification of CJC-1295 as a long-lasting GRF analog<\/strong><\/a>.<\/p>\n

\n\n\n\n\n\n\n\n\n
Labeling<\/th>\nResearch context<\/th>\nImportant restriction<\/th>\n<\/tr>\n<\/thead>\n
GRF(1-29)<\/strong><\/td>\nAkt\u00edvny fragment growth hormone-releasing factor sk\u00faman\u00fd v GHRH receptorovej signaliz\u00e1cii.<\/td>\nNie je toto\u017en\u00fd s dlho p\u00f4sobiacim CJC-1295.<\/td>\n<\/tr>\n
CJC-1295 s DAC<\/strong><\/td>\nAlbum\u00edn-via\u017euci, dlho p\u00f4sobiaci GHRH anal\u00f3g sk\u00faman\u00fd aj v kontrolovan\u00fdch \u013eudsk\u00fdch \u0161t\u00fadi\u00e1ch.<\/td>\nV\u00fdsledky tejto formy nemo\u017eno automaticky prenies\u0165 na No DAC materi\u00e1l.<\/td>\n<\/tr>\n
CJC-1295 No DAC \/ Mod GRF 1-29<\/strong><\/td>\nKatal\u00f3gov\u00e9 ozna\u010denie pou\u017e\u00edvan\u00e9 pre kr\u00e1tko p\u00f4sobiace modifikovan\u00e9 GRF(1-29) research materi\u00e1ly.<\/td>\nSamostatn\u00e9 klinick\u00e9 \u00fadaje \u0161pecifick\u00e9 pre t\u00fato komer\u010dne ozna\u010dovan\u00fa formu s\u00fa podstatne obmedzenej\u0161ie.<\/td>\n<\/tr>\n
Ipamorelin<\/strong><\/td>\nPentapeptidov\u00fd growth hormone secretagogue sk\u00faman\u00fd cez odli\u0161n\u00fa receptorov\u00fa dr\u00e1hu.<\/td>\nV\u00fdsledky \u0161t\u00fadi\u00ed Ipamorelinu automaticky nedokazuj\u00fa vlastnosti jeho kombin\u00e1cie s GRF anal\u00f3gom.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

\u010co uk\u00e1zali \u013eudsk\u00e9 \u0161t\u00fadie CJC-1295?<\/h2>\n

Kontrolovan\u00e9 \u0161t\u00fadie publikovan\u00e9 v roku 2006 sk\u00famali dlho p\u00f4sobiaci CJC-1295<\/strong>, nie materi\u00e1l ozna\u010dovan\u00fd v research katal\u00f3goch ako No DAC.<\/p>\n

V randomizovan\u00fdch \u0161t\u00fadi\u00e1ch u zdrav\u00fdch dospel\u00fdch sa sledovala farmakokinetika a zmeny koncentr\u00e1ci\u00ed GH a IGF-I po expoz\u00edcii dlho p\u00f4sobiacemu CJC-1295. V\u00fdskumn\u00edci zaznamenali pred\u013a\u017een\u00fa expoz\u00edciu a zmeny sledovan\u00fdch hormon\u00e1lnych parametrov.<\/p>\n

Podrobnosti s\u00fa dostupn\u00e9 v p\u00f4vodnej publik\u00e1cii:<\/p>\n

Teichman et al. \u2013 Prolonged stimulation of GH and IGF-I secretion by CJC-1295<\/strong><\/a>.<\/p>\n

\u010eal\u0161ia pr\u00e1ca n\u00e1sledne analyzovala pulzatilitu GH po\u010das pred\u013a\u017eenej expoz\u00edcie tejto dlho p\u00f4sobiacej formy:<\/p>\n

Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295<\/strong><\/a>.<\/p>\n

Tieto publik\u00e1cie maj\u00fa v\u00fdznam pre pochopenie GHRH receptorovej signaliz\u00e1cie a farmakol\u00f3gie CJC-1295 s album\u00ednovou v\u00e4zbou. Nie s\u00fa v\u0161ak priamym klinick\u00fdm d\u00f4kazom pre CJC-1295 No DAC ani pre kombin\u00e1ciu CJC-1295 No DAC + Ipamorelin.<\/strong><\/p>\n

Pre\u010do sa Ipamorelin a GRF anal\u00f3gy sk\u00famaj\u00fa v rozdielnych receptorov\u00fdch dr\u00e1hach?<\/h2>\n

Regul\u00e1cia somatotropnej osi je v\u00fdsledkom interakcie viacer\u00fdch sign\u00e1lov. GHRH receptorov\u00e1 dr\u00e1ha a growth hormone secretagogue receptorov\u00e1 dr\u00e1ha predstavuj\u00fa dva rozdielne mechanizmy, ktor\u00e9 m\u00f4\u017eu ovplyv\u0148ova\u0165 aktivitu somatotrofn\u00fdch buniek hypof\u00fdzy.<\/p>\n

\n\n\n\n\n\n\n\n\n
V\u00fdskumn\u00fd materi\u00e1l<\/th>\nPrim\u00e1rny v\u00fdskumn\u00fd cie\u013e<\/th>\nTyp dostupn\u00fdch d\u00f4kazov<\/th>\n<\/tr>\n<\/thead>\n
Ipamorelin<\/strong><\/td>\nGHS\/GHRP receptorov\u00e1 signaliz\u00e1cia<\/td>\nMechanistick\u00e9 \u00fadaje z bunkov\u00fdch a zvierac\u00edch modelov (Raun et al., 1998)<\/td>\n<\/tr>\n
GRF(1-29) anal\u00f3gy<\/strong><\/td>\nGHRH receptorov\u00e1 signaliz\u00e1cia<\/td>\nMechanistick\u00e9 a experiment\u00e1lne \u00fadaje vr\u00e1tane star\u0161\u00edch kontrolovan\u00fdch \u0161t\u00fadi\u00ed GRF<\/td>\n<\/tr>\n
CJC-1295 s DAC<\/strong><\/td>\nPred\u013a\u017een\u00e1 GHRH receptorov\u00e1 stimul\u00e1cia<\/td>\nPredklinick\u00e9 a kontrolovan\u00e9 \u013eudsk\u00e9 farmakokinetick\u00e9\/farmakodynamick\u00e9 \u0161t\u00fadie<\/td>\n<\/tr>\n
Ipamorelin + CJC-1295 No DAC<\/strong><\/td>\nKombinovan\u00e9 sk\u00famanie dvoch odli\u0161n\u00fdch receptorov\u00fdch dr\u00e1h<\/td>\nPriame klinick\u00e9 \u00fadaje pre samotn\u00fa kombin\u00e1ciu s\u00fa obmedzen\u00e9<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

Je kombinovan\u00fd \u00fa\u010dinok klinicky potvrden\u00fd?<\/h2>\n

Nie je vhodn\u00e9 tvrdi\u0165, \u017ee kombin\u00e1cia Ipamorelin + CJC-1295 No DAC m\u00e1 klinicky potvrden\u00fd synergick\u00fd \u00fa\u010dinok.<\/strong><\/p>\n

Mechanisticky ide o l\u00e1tky spojen\u00e9 s rozdielnymi receptorov\u00fdmi syst\u00e9mami, \u010do vytv\u00e1ra zauj\u00edmav\u00fa v\u00fdskumn\u00fa ot\u00e1zku. Samotn\u00e1 mechanistick\u00e1 logika v\u0161ak nie je n\u00e1hradou za priamu kontrolovan\u00fa \u0161t\u00fadiu konkr\u00e9tnej kombin\u00e1cie.<\/p>\n

Rovnako nie je spr\u00e1vne prebera\u0165 farmakokinetick\u00e9 \u00fadaje CJC-1295 s DAC a prezentova\u0165 ich ako vlastnosti materi\u00e1lu bez DAC.<\/p>\n

Pri vedeckom hodnoten\u00ed je preto vhodn\u00e9 odde\u013eova\u0165:<\/p>\n